<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364709">
  <stage>Registered</stage>
  <submitdate>1/08/2013</submitdate>
  <approvaldate>8/08/2013</approvaldate>
  <actrnumber>ACTRN12613000888763</actrnumber>
  <trial_identification>
    <studytitle>Study of the effect of Serenoa Repens on prostatic inflammation</studytitle>
    <scientifictitle>Does treatment with Serenoa Repens results in improvement of inflammation score compared to no treatment, in men with histologically prostatic inflammation?</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prostatic inflammation</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with prostatic inflammation based on biopsy result are randomized to receive either Serenoa Repens (oral capsules for 6 months) 320mg daily (Group 1) or no treatment (Group 2). Monitoring will be based on patients' tablet return.</interventions>
    <comparator>Active, no treatment</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Inflammation score (Irani et al 1997)

</outcome>
      <timepoint>Six months after intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Immunohistochemical study of inflammation
- CD3, CD4, CD8 T-lymphocytes 
- CD20 B-lymphocytes
- CD163 macrophages
The outcome will be assesed depending on prostate biopsy results. </outcome>
      <timepoint>Six months after intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with proven inflammation in prostatic biopsy</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who have been already treated for LUTS with herbal medication.
Patients who have been diagnosed with prostate cancer at the first biopsy. 
Patients who underwent pelvic radiotherapy for any reason.
Patients with a permanent urethral catheter.
Patient with a previous TURP or intravesical instillations due to bladder cancer.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>www.randomizer.org, central randomization by computer</concealment>
    <sequence>Simple randomization using a randomization table created by computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Nil</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>We estimated, using current data, that a significant difference in inflammation score could be standarized at 25%. Power of the study was calculated at 90%, using https://www.dssresearch.com power calculator, so each Group should have 50 enrollments (totally 100).
Statistical analysis of our results will take place using non-parametrical methods.</statisticalmethods>
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/07/2012</anticipatedstartdate>
    <actualstartdate>20/07/2012</actualstartdate>
    <anticipatedenddate>31/12/2014</anticipatedenddate>
    <actualenddate>22/12/2014</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>13/07/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaly</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Department of Urology, University of Thessaly</primarysponsorname>
    <primarysponsoraddress>Viopolis Mezourlo
41335
Larisa</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Department of Urology, University of Thessaly</fundingname>
      <fundingaddress>Viopolis Mezourlo
41335
Larisa</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to determine the effect of Serenoa Repens use on prostatic inflammation, based on histological and immunohistochemical criteria. Patients with prostatic inflammation based on biopsy results are randomized to receive either Serenoa Repens 320mg/d (Group 1) or no treatment (Group 2).  Patients will receive a second biopsy 6 months later. Inflammation score and immunohistochemical results, with or without treatment with Serenoa Repens, will be statistically compared, so as to evaluate the effect on the prostatic inflammation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Scientific Committee University Hospital of Larisa </ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/06/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Greece</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Gravas Stavros, Urology Assistant Profesor, Urology Department of University of Thessaly</name>
      <address>Urology Assistant Profesor, Urology Department of University of Thessaly
Viopolis Mezourlo
41335
Larisa</address>
      <phone>+306944626086</phone>
      <fax />
      <email>sgravas2002@yahoo.com</email>
      <country>Greece</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Samarinas Michael Urology Resident, Urology Department of University of Thessaly</name>
      <address>Urology Resident, Urology Department of University of Thessaly
Viopolis Mezourlo
41335
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Gravas Stavros Urology Assistant Professor, Urology Department of University of Thessaly</name>
      <address>Urology Assistant Professor, Urology Department of University of Thessaly
Viopolis Mezourlo
41335
Larisa</address>
      <phone>+306944626086</phone>
      <fax />
      <email>sgravas2002@yahoo.com</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Samarinas Michael</name>
      <address>Viopolis Mezourlo
41335
Larisa</address>
      <phone>+306946006798</phone>
      <fax />
      <email>mikesamih@hotmail.com</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>